Reviewing Orchestra BioMed (OBIO) and Its Peers

Orchestra BioMed (NASDAQ:OBIO) is one of 230 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Orchestra BioMed to related companies based on the strength of its dividends, valuation, risk, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Orchestra BioMed and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Orchestra BioMed	-1,779.71%	-58.32%	-41.47%
Orchestra BioMed Competitors	-748.42%	-148.96%	-29.52%

Insider and Institutional Ownership

53.5% of Orchestra BioMed shares are owned by institutional investors. Comparatively, 48.2% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.4% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Volatility and Risk

Orchestra BioMed has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, Orchestra BioMed’s peers have a beta of 1.12, suggesting that their average share price is 12% more volatile than the S&P 500.

Valuation and Earnings

This table compares Orchestra BioMed and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Orchestra BioMed	$2.76 million	-$49.12 million	-2.93
Orchestra BioMed Competitors	$1.05 billion	$4.46 million	-7.62

Orchestra BioMed’s peers have higher revenue and earnings than Orchestra BioMed. Orchestra BioMed is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent ratings for Orchestra BioMed and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orchestra BioMed	0	0	2	0	3.00
Orchestra BioMed Competitors	1592	4301	8422	223	2.50

Orchestra BioMed currently has a consensus price target of $17.00, suggesting a potential upside of 287.24%. As a group, “Surgical & medical instruments” companies have a potential upside of 29.07%. Given Orchestra BioMed’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Orchestra BioMed is more favorable than its peers.

Summary

Orchestra BioMed peers beat Orchestra BioMed on 7 of the 13 factors compared.

Orchestra BioMed Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.